Actos Lawsuit Update: December 13th Set for Next Status Conference in Federal Actos Bladder Cancer Lawsuits

Share Article

As Actos bladder cancer litigation moves forward, Bernstein Liebhard LLP continues to investigate potential Actos lawsuits on behalf of people who developed bladder cancer, allegedly due to the popular type 2 diabetes medication.

Bernstein Liebhard LLP | Consumer Injury Lawyers
We continue to receive inquiries from Actos users who developed bladder cancer that could very well be tied to their use of this drug.

Actos lawsuits pending in a federal multidistrict litigation now underway in U.S. District Court, Western District of Louisiana continue to move forward, Bernstein Liebhard LLP reports. According to the Court’s calendar, the next Status Conference in the federal Actos bladder cancer litigation has been scheduled for 10:30 a.m. on December 13, 2012. (In re: Actos (Pioglitazone) Products Liability Litigation - MDL No. 2299)

“We continue to receive inquiries from Actos users who developed bladder cancer that could very well be tied to their use of this drug,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The firm is currently offering free Actos bladder cancer lawsuit evaluations to alleged victims of this medication.

Actos Bladder Cancer Lawsuits
Actos lawsuits pending in the federal litigation allege that Takeda Pharmaceuticals and other defendants concealed knowledge that the type 2 diabetes medication increased the risk of bladder cancer, and failed to provide patients with adequate warnings regarding the risk. The U.S. Judicial Panel on Multidistrict Litigation established the consolidated litigation in anticipation of a large number of Actos lawsuit filings in federal courts throughout the U.S.
In June 2011, the U.S. Food & Drug Administration (FDA) mandated new warnings for the Actos label after a study found that long-term use of the drug increased the risk for bladder cancer.*

Since then, even more research has confirmed the association between Actos and the disease. In May 2012, a British Medical Journal study concluded that taking Actos for two years can double the risk of developing bladder cancer. ** Research published in the Canadian Medical Association Journal in July 2012 concluded that patients taking Actos face a 22 percent increased risk of developing bladder cancer. *** While Actos is still available in the U.S., it has been pulled from the market in both Germany and France.****

Actos users who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website, For additional information, contact a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website